276 related articles for article (PubMed ID: 33467481)
1. Osteosarcoma Pathogenesis Leads the Way to New Target Treatments.
Fernandes I; Melo-Alvim C; Lopes-Brás R; Esperança-Martins M; Costa L
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467481
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
3. The possible role of insulin-like growth factor-1 in osteosarcoma.
Li YS; Liu Q; He HB; Luo W
Curr Probl Cancer; 2019 Jun; 43(3):228-235. PubMed ID: 30217668
[TBL] [Abstract][Full Text] [Related]
4. HER-2 involvement in osteosarcoma.
Gill J; Geller D; Gorlick R
Adv Exp Med Biol; 2014; 804():161-77. PubMed ID: 24924174
[TBL] [Abstract][Full Text] [Related]
5. Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies.
Xiao H; Jensen PE; Chen X
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491952
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.
Scotlandi K; Manara MC; Hattinger CM; Benini S; Perdichizzi S; Pasello M; Bacci G; Zanella L; Bertoni F; Picci P; Serra M
Eur J Cancer; 2005 Jun; 41(9):1349-61. PubMed ID: 15913990
[TBL] [Abstract][Full Text] [Related]
7. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
Shaikh AB; Li F; Li M; He B; He X; Chen G; Guo B; Li D; Jiang F; Dang L; Zheng S; Liang C; Liu J; Lu C; Liu B; Lu J; Wang L; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):506. PubMed ID: 27058531
[TBL] [Abstract][Full Text] [Related]
8. The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor.
Chen KT; Hour MJ; Tsai SC; Chung JG; Kuo SC; Lu CC; Chiu YJ; Chuang YH; Yang JS
Int J Oncol; 2011 Sep; 39(3):611-9. PubMed ID: 21667022
[TBL] [Abstract][Full Text] [Related]
9. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.
Wang W; Zhao HF; Yao TF; Gong H
Invest New Drugs; 2019 Feb; 37(1):175-183. PubMed ID: 30353245
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer targets of formononetin and molecular mechanisms in osteosarcoma: Findings of bioinformatic and experimental assays.
Hu W; Wu X; Tang J; Zhao G; Xiao N; Zhang L; Li S
J Cell Mol Med; 2019 May; 23(5):3505-3511. PubMed ID: 30873755
[TBL] [Abstract][Full Text] [Related]
11. [Her2 a paradigm for targeted therapy].
Marijon H; André F
Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
[TBL] [Abstract][Full Text] [Related]
12. HER2-Targeted Therapy in Osteosarcoma.
Gill J; Hingorani P; Roth M; Gorlick R
Adv Exp Med Biol; 2020; 1257():55-66. PubMed ID: 32483730
[TBL] [Abstract][Full Text] [Related]
13. Association of anti-HER2 antibody with graphene oxide for curative treatment of osteosarcoma.
Li L; Luo C; Song Z; Reyes-Vargas E; Clayton F; Huang J; Jensen P; Chen X
Nanomedicine; 2018 Feb; 14(2):581-593. PubMed ID: 29170110
[TBL] [Abstract][Full Text] [Related]
14. mTOR: An attractive therapeutic target for osteosarcoma?
Ding L; Congwei L; Bei Q; Tao Y; Ruiguo W; Heze Y; Bo D; Zhihong L
Oncotarget; 2016 Aug; 7(31):50805-50813. PubMed ID: 27177330
[TBL] [Abstract][Full Text] [Related]
15. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response.
Dong J; Demarest SJ; Sereno A; Tamraz S; Langley E; Doern A; Snipas T; Perron K; Joseph I; Glaser SM; Ho SN; Reff ME; Hariharan K
Mol Cancer Ther; 2010 Sep; 9(9):2593-604. PubMed ID: 20716637
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
Anderson PM; Bielack SS; Gorlick RG; Skubitz K; Daw NC; Herzog CE; Monge OR; Lassaletta A; Boldrini E; Pápai Z; Rubino J; Pathiraja K; Hille DA; Ayers M; Yao SL; Nebozhyn M; Lu B; Mauro D
Pediatr Blood Cancer; 2016 Oct; 63(10):1761-70. PubMed ID: 27362300
[TBL] [Abstract][Full Text] [Related]
17. Herceptin: A First Assault on Oncogenes that Launched a Revolution.
Sawyers CL
Cell; 2019 Sep; 179(1):8-12. PubMed ID: 31519311
[TBL] [Abstract][Full Text] [Related]
18. New molecular insights into osteosarcoma targeted therapy.
Yang J; Zhang W
Curr Opin Oncol; 2013 Jul; 25(4):398-406. PubMed ID: 23666471
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
Chen S; Liang Y; Feng Z; Wang M
BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
[TBL] [Abstract][Full Text] [Related]
20. The Targeted Therapies for Osteosarcoma
Wang S; Ren Q; Li G; Zhao X; Zhao X; Zhang Z
Curr Mol Pharmacol; 2024; 17(1):e210823220109. PubMed ID: 37602543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
